Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease.
Lisa DennyAfnan Al AbadeyKatharina RobichonNikki TempletonThomas E PrisinzanoBronwyn M KivellAnne Camille La FlammePublished in: Clinical & translational immunology (2021)
Overall, our findings support the potential of nalfurafine to promote recovery and remyelination and highlight its promise for clinical use in MS.